Life Sciences Report

The market for tissue engineered products to exceed $4.8 billion by the year 2028

Tissue Engineering 2018-2028: Technologies, Markets, Forecasts

Opportunities for living tissue equivalents and technologies for their manufacture

Brand new for November 2017

 
Tissue engineering, referring to the technologies that use physical, chemical, biological and engineering processes to control and direct the aggregate behaviour of cells, has become a field of increasing commercial interest. Though tissue engineering as a field has been around since the late 1970s, there have been few commercial successes. However, human understanding of biology, and our ability to manipulate it, has finally reached a point where complex living tissue equivalents are being developed. This report investigates this next generation of tissue engineering products and their potential in the next 10 years.
 
This report covers living tissue equivalents which contain both living cells and a 3D structure.
 
Applications
The biggest applications for engineered tissues are in research and development, and in medicine. This report discusses the following key applications of tissue engineering:
 
  • Testing of cosmetics and other consumer goods
  • Drug screening
  • Personalized medicine
  • Regenerative medicine
  • Cell-based biosensors
  • Food and other animal products
  • Aesthetics
 
Clinical Landscape
A chapter of this report is dedicated to the use of tissue engineering products in medicine. The following classes of tissue engineered therapies are highlighted:
 
  • Tissue engineered therapies with FDA marketing approval
  • Tissue engineered therapies close to IND submission
  • Competitive landscape of tissue engineered skin
  • Competitive landscape of tissue engineered cartilage
 
Additionally, a summary of ongoing clinical trials of tissue engineered products is provided, organized by trial phase, tissue type, and sponsor.
 
The rest of this chapter describes and discusses the dynamics of US and EU markets, with a look at relevant regulatory pathways, exemptions, and loopholes for tissue engineered products, as well as speculations on the future of regulating this novel class of therapy.
 
Market Forecasts
A market forecast for tissue engineered products is provided for the years 2018 - 2028, where the total value for tissue engineered products is predicted to surpass $4.8 billion. This market is broken down into key applications of therapies (clinical use) and tissue models (research use). Key players in both applications are presented, and the value chain and relevant business models are discussed.
 
Separately, a forecast for 3D bioprinters, an up-and-coming technology for tissue engineering, is also provided for the years 2018 - 2028.
 
Technology
A wide range of approaches are still being explored in tissue engineering, and this report covers both the most innovative and cutting-edge techniques as well as more established technologies. Technologies presented in this report are:
 
  • Semi-permeable membranes
  • Cell-laden hydrogels
  • 3D bioprinting
  • 3D printing (including thermoplastic extrusion, material jetting, stereolithography, selective laser sintering)
  • Decelluarization and recellularization of organs
  • Phase separation, freeze-drying, solvent casting and particle leaching, gas foaming
  • Electrospinning and melt electrospinning
  • Self-assembly and self-organization
Analyst access from IDTechEx
All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.
Further information
If you have any questions about this report, please do not hesitate to contact our report team at research@IDTechEx.com or call one of our sales managers:
 
Americas (US): +1 617 577 7890
Europe (UK): +44 (0)1223 812300
Korea: +82 31 263 7890
Rest of Asia (Japan): +81 90 1704 1184
Table of Contents
1.EXECUTIVE SUMMARY
1.1.Overview
1.2.What is Tissue Engineering?
1.3.How are Tissues Engineered?
1.4.Key Players
1.5.Key Drivers
1.6.Key Opportunities
1.7.Tissue Engineered Products Market Forecast 2018 - 2028
1.8.Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028
1.9.Tissue Engineered Products for Research Use Market Forecast 2018 - 2028
1.10.Key Technologies
1.11.Key Challenges
2.INTRODUCTION
2.1.Report Scope
2.2.Advantages of 3D Cell Culture
2.3.Key Driver: Regenerative Medicine
2.4.Key Driver: Unmet Need in Organs for Transplant
2.5.Key Driver: Product Testing in Medicine
2.6.Key Driver: Avoiding Costly Drug Trial Failures
2.7.Key Driver: Product Testing in Consumer Products
2.8.Current Challenges: Biological
2.9.Current Challenges: Commercialization
2.10.Tissue Engineering in 2017
3.KEY OPPORTUNITIES
3.1.Overview
3.2.Testing of Cosmetics and Other Consumer Goods
3.3.Product Testing: Companies
3.4.Product Testing:
3.5.Drug Screening: Dermagenist
3.6.Drug Screening: Drug Development Process
3.7.Drug Screening: Benefits of Tissue Engineering
3.8.Drug Screening: Cancer
3.9.Drug Screening: Organ-on-a-chip
3.10.Drug Screening: Companies
3.11.Personalised Medicine
3.12.Cell-Based Biosensors
3.13.Food and Other Animal Products
3.14.Esthetics
4.TISSUE ENGINEERING CLINICAL LANDSCAPE
4.1.Overview
4.2.Regenerative Medicine
4.3.Competing Products
4.4.Competing Products: Advantages and Disadvantages
4.5.Commercial Activity
4.6.The US Market
4.7.Products with FDA Marketing Approval
4.8.The European Market
4.9.Clinical Trials
4.10.Clinical Trials: By Indication and Phase
4.11.Skin: Clinical Products
4.12.Cartilage: Clinical Products
4.13.Cartilage: NeoCart
4.14.Pre-Clinical Products
4.15.Regulatory Exemptions
4.16.Hospital Exemption Scheme
4.17.Hospital Exemption Scheme: Problems
4.18.21st Century Cures Act and the Regenerative Medicine Advanced Therapy Designation
4.19.Orphan Drug Designation
4.20.Scams and Unauthorized Treatments
4.21.Moving to Conditional Approval
4.22.Moving to Conditional Approval: Case Study
4.23.Learning from Medical Innovations
4.24.Future
5.MARKETS AND FORECASTS
5.1.Overview
5.2.Market Barriers
5.3.Tissue Engineering Value Chain
5.4.Tissue Engineering Value Chain: Discussion
5.5.Forecasts
5.6.Tissue Engineered Products Market Forecast 2018 - 2028
5.7.Companies with Marketed Clinical Products
5.8.Companies Developing Engineered Tissues for Clinical Use
5.9.Business Models: Engineered Autologous Tissues
5.10.Business Models: Cryopreserved Allogeneic Tissues
5.11.Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028
5.12.Companies Engineering Tissues for Research Use
5.13.Business Models: Tissues for Research Use
5.14.Tissue Engineered Products for Research Use Market Forecast 2018 - 2028
5.15.Companies Producing Organ-On-A-Chips
5.16.Companies Producing Lab-Grown Meat
5.17.Scaffold Manufacturers
5.18.3D Bioprinter Market and Forecasts
5.19.Growing 3D Bioprinting Market
5.20.3D Bioprinting Value Chain
5.21.3D Bioprinting Value Chain: Discussion
5.22.3D Bioprinters by Cost and Technology
5.23.3D Bioprinter Market Forecast 2018 - 2028
5.24.Caveats
6.TISSUE ENGINEERING TECHNOLOGIES
6.1.Overview
7.ESTABLISHED TECHNOLOGIES
7.1.Introduction
7.2.Semi-Permeable Membranes
7.3.Key Semi-Permeable Membrane Manufacturers
7.4.Hydrogels
7.5.Cell-Laden Hydrogels
7.6.Cell-Laden Hydrogels: Companies
7.7.Cell-Laden Hydrogels: SWOT Analysis
8.3D BIOPRINTING
8.1.Introduction
8.2.3D Bioprinting Process
8.3.Comparison of Key Specifications
8.4.3D Bioprinting Technology Comparison
8.5.Inkjet: Thermal
8.6.Inkjet: Piezoelectric
8.7.Inkjet: Companies
8.8.Inkjet: SWOT Analysis
8.9.Extrusion: Pneumatic
8.10.Extrusion: Mechanical
8.11.Extrusion: Companies
8.12.Extrusion: Example
8.13.Extrusion: SWOT Analysis
8.14.LIFT: Laser-Induced Forward Transfer
8.15.LIFT: Companies
8.16.LIFT: SWOT Analysis
8.17.Microvalve: Solenoid
8.18.Microvalve: Companies
8.19.Microvalve: SWOT Analysis
8.20.Industry-wide Technical Challenges
8.21.The Ideal 3D Bioprinter
8.22.Animal Studies
8.23.Future Technological Directions
9.SCAFFOLD TECHNOLOGIES
9.1.Tissue Engineering Scaffolds
9.2.Ideal Scaffold
10.3D PRINTING
10.1.Introduction
10.2.Examples of 3D Printed Medical Products
10.3.Thermoplastic Extrusion
10.4.Thermoplastic Extrusion: Example
10.5.Thermoplastic Extrusion: Key Manufacturers
10.6.Thermoplastic Extrusion: SWOT Analysis
10.7.Material Jetting
10.8.Material Jetting: Key Players
10.9.Material Jetting: SWOT Analysis
10.10.Stereolithography
10.11.Stereolithography: Key Players
10.12.Stereolithography: SWOT Analysis
10.13.Stereolithography: Microstereolithography
10.14.Stereolithography: Projection
10.15.Stereolithography: Multiphoton Lithography
10.16.Stereolithography: Multiphoton Lithography: Example
10.17.Selective Laser Sintering
10.18.Selective Laser Sintering: Key Players
10.19.Selective Laser Sintering: SWOT Analysis
11.DECELLULARIZED ORGANS
11.1.Introduction
11.2.History
11.3.Decellularization
11.4.Recellularization
11.5.Companies
11.6.Future Technological Directions
11.7.Bioreactors
12.OTHER SCAFFOLD TECHNOLOGIES
12.1.Introduction
12.2.Phase Separation
12.3.Freeze-Drying
12.4.Freeze-Drying: Companies
12.5.Solvent Casting and Particle Leaching
12.6.Gas Foaming
12.7.Chemical Processes: Strengths and Weaknesses
12.8.Textile Technologies
12.9.Electrospinning
12.10.Cell Electrospinning
12.11.Electrospinning: Examples
12.12.Electrospinning: SWOT Analysis
12.13.Melt Electrospinning
12.14.Melt Electrospinning: SWOT Analysis
12.15.Electrospinning: Companies
13.SCAFFOLDLESS TECHNOLOGIES
13.1.Introduction
13.2.Cell Spheroids
13.3.Cell Spheroids: Self-Assembly
13.4.Cell Spheroids: Self-Organization
13.5.Cell Spheroids: Rotational Culture Equipment
13.6.Cell Spheroids: Key Companies
13.7.Cell Sheets
13.8.Cell Therapy Devices
13.9.Cell Therapy Devices: Companies
14.TISSUE ENGINEERING CHALLENGES
14.1.Industry-Wide Technical Challenges
14.2.Biopreservation
14.3.Vascularization
15.COMPANY PROFILES
15.1.3D Bioprinting Solutions/ Vivax Bio
15.2.3D Biotek
15.3.3Dynamic Systems Ltd
15.4.Aether Inc.
15.5.Aspect Biosystems
15.6.ATERA
15.7.Avery Therapeutics
15.8.AxoSim
15.9.BioBots
15.10.BioDan Group
15.11.BIOLIFE4D
15.12.Cellenion SASU
15.13.Cellf BIO
15.14.Cellink
15.15.CUTISS
15.16.Digilab Inc.
15.17.GeSiM
15.18.Hesperos
15.19.Histogenics
15.20.Lena Biosciences
15.21.Microdrop Technologies GmbH
15.22.MicroFab Technologies
15.23.Mimetas
15.24.PeptiGel Design Ltd
15.25.Poietis
15.26.Presllis Biologics
15.27.Regemat 3D
15.28.RegenHU
15.29.SE3D
15.30.Sichuan Revotek Co. Ltd.
15.31.Synthecon
15.32.Tara Biosystems
15.33.TissUse
15.34.Upside Biotechnologies

Ordering Information

 
 
-Electronic (1-5 users)$4,995.00
-Electronic (6-10 users)$7,495.00
-Electronic and 1 Hardcopy (1-5 users)$5,295.00
-Electronic and 1 Hardcopy (6-10 users)$7,795.00
Click here to enquire about additional licenses.
If you are a reseller/distributor please contact us before ordering.
お問合せ、見積および請求書が必要な方はm.murakoshi@idtechex.com までご連絡ください。

Report Statistics

-Slides187
-Companies34
-Forecasts to2028
-Last updateJan 2018
 

Downloads

pdf Document Webinar Slides
pdf Document Sample pages